| Previous Close | 83.02 |
| Open | 82.87 |
| Bid | 82.87 x 200 |
| Ask | 82.90 x 500 |
| Day's Range | 82.51 - 83.22 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 1,667,485 |
| Avg. Volume | 3,690,290 |
| Market Cap | 87.33B |
| Beta | 0.17 |
| PE Ratio (TTM) | 40.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.53%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Market Realist•3 hours ago
Pfizer on the Street: Inside the Analysts’ Recommendations
No analyst has recommended any form of "sell" for Pfizer stock.
- Bloomberg•22 hours ago
Overhaul Drug R&D? Easier Said Than Done
Both in-house and M&A solutions will be risky and take time to bear fruit.
- Forbes•yesterday
Diabetes Crisis Continues To Rage, But Biopharma's Response Is Tepid
If you were running an R&D organization, would you use your precious resources to invest in diabetes R&D, or would you look at other important areas like cancer and rare diseases, where the need is great but the ultimate development costs are less?
